Quick Takeaways: Why It Matters? The EUA makes ivermectin liquid a short-term, horse-only screwworm prophylaxis tool, adding another regulated option to the NWS armamentarium and slightly strengthening biosecurity for foals and wounded horses, but because protection lasts only 24 hours and...
Quick Takeaways: Why It Matters? Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a ...
Quick Takeaways: Why It Matters? The partnership gives PetMeds a new revenue channel and accelerates AutoShip adoption (recurring orders of eligible meds, preventatives, and prescription diets), while Rural King customers gain a convenient, trusted pharmacy option with sitewide 25% off and...
Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
Quick Takeaways: Why It Matters? Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s nationa...
Quick Takeaways: Why It Matters? Dechra’s Boston HQ move and community-facing strategy signal how veterinary pharma is increasingly aligning with mainstream human health and life sciences ecosystems, not just traditional animal-health hubs, which could intensify competition for talent, par...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Quick Takeaways: Why It Matters? Gelteq’s canine palatability trials with Kemin confirm that its gel-based delivery platform can effectively mask bitter compounds and deliver strong acceptance across multiple flavor profiles, even with naturally unpalatable ingredients. This is a key enabl...
Quick Takeaways: Why It Matters? Cronus Pharma is bringing price competition to a key canine heart failure drug class by launching the first FDA‑approved bioequivalent chewable to Vetmedin, available nationwide through vet distributors. For the market, this should lo...
